



PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/579,705
Filing Date	October 31, 2008
First Named Inventor	George J. Christ
Art Unit	1633
Examiner Name	Quang Nguyen, Ph.D.
Attorney Docket Number	96700/1139

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/QN/	1	FOSTER D N et al., Positive and Negative cis-Acting Regulatory Elements Mediate Expression of the Mouse Vascular Smooth Muscle alpha-Action Gene, The Journal of Biological Chemistry, June 15, 1992, Vol. 267, NO. 17, pp. 11995-12003.	
	2	CHANG P C et al., Muscle Specificity Encoded by Specific Serum Response, The Journal of Biological Chemistry, May 18, 2001, Vol. 276, No. 20, pp. 17206-17212.	
	3	SATO Y, The current situation and the future for ED treatment, Urological Surgery, Japan, Vol. 14, No. 11, pp. 1221-1226, November 15, 2001.	
	4	SATO Y et al., Male Sexual Dysfunctions, treatment for erectile disorder, "Gene therapy and tissue engineering for erectile dysfunction," Male Sexual Dysfunctions, Japanese Journal of Clinical Medicine, Japan, Vol. 60, Extra No. 6, pp. 310-314, June 28, 2002.	
	5	SATO Y et al., Gene Therapy with Maxi-K+ Channels Restores Diminished Erectile Resposne in Older Animals During Electrical Stimulation of the Medial Preoptic Area (MPOA), The Journal of Urology, 2000, Vol. 163, No. 4, Supplement, pp. 198-199.	
/QN/	6	SATO Y et al., The Effects of Gene Therapy with Maxi-K+ Channels Apomorphine-Evoked Increases in Intracavernous Pressure in the Awake Rats, The Journal of Urology, 2001, Vol. 165, No. 5, Supplement, p. 220.	

Examiner Signature	/Quang Nguyen/	Date Considered	10/28/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/579,705
Filing Date	October 31, 2008
First Named Inventor	George J. Christ
Art Unit	1633
Examiner Name	Quang Nguyen, Ph.D.
Attorney Docket Number	96700/1139

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/QN/	7	THORNE G D et al., Hypoxic vasorelaxation inhibition by organ culture correlates with loss of Kv channels but not Ca2+ channels, American Journal of Physiology-Heart and Circulatory Physiology, July 2002, Vol. 283, No. 1, Pt. 2, pp. H247-H253.	
/QN/	8	KIMURA et al., Analysis of pathogeny for arteriosity erectile dysfunction "Smooth muscle content in corpus cavernosum penis and the relaxant response" Summary for conference presentation in the Pharmaceutical Society of Japan, Vol. 123rd, No. 4, p. 34, March 5, 2003.	
/QN/	9	UEBELE V N et al., Functional Differences in Kv1.5 Currents Expressed in Mammalian Cell Lines Are Due to the Presence of Endogeneous Kv B2. 1 Subunits, The Journal of Biological Chemistry, February 2, 1996, Vol. 271, No. 5, PP. 2406-2412.	

Examiner Signature	/Quang Nguyen/	Date Considered	10/28/2010
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.